Does retatrutide cause muscle loss?

Short answer: any large, fast weight loss takes some lean mass with it, and retatrutide is no exception. The one body-composition study published so far reports that the share of weight lost as lean tissue was similar to what other obesity treatments produce^[1]. So the honest framing is not that retatrutide melts muscle, but that it drives large weight loss, and a predictable slice of that weight is fat-free mass rather than fat.

There is an important caveat before the detail. Retatrutide is investigational. It has no marketing authorisation from the FDA, EMA, MHRA, or any agency we cover, and the muscle-loss evidence base is thin. One dedicated body-composition substudy exists, and everything else is inference from the wider drug class. We will be clear about which is which.

What the one retatrutide body-composition study measured

The direct evidence comes from a substudy of the Phase 2 type-2 diabetes trial, published by Coskun and colleagues in Lancet Diabetes & Endocrinology in 2025^[1]. Researchers used DXA scans (dual-energy X-ray absorptiometry, the standard way to split body weight into fat and fat-free mass) on participants who had both a baseline and a week-36 measurement. Of 189 people enrolled in the substudy, 103 completed both scans, so the numbers rest on a small sample.

Fat mass fell substantially: about 15.2% on the pooled 4 mg arms, 26.1% on the pooled 8 mg arms, and 23.2% on 12 mg at week 36, against 4.5% on placebo and 2.6% on dulaglutide^[1]. The line that answers the muscle-loss question is the authors' own conclusion: the proportion of lean mass loss relative to total weight loss was similar to other obesity treatments. In plain terms, retatrutide lost more total weight than the comparators, but it did not shift the fat-to-lean ratio in a worse direction.

How that compares with the wider GLP-1 class

The best-characterised body-composition picture in this class comes from tirzepatide, the dual GLP-1 and GIP agonist. A DXA substudy of SURMOUNT-1, published in Diabetes, Obesity and Metabolism in 2025, tracked 160 participants to week 72^[2]. Body weight fell 21.3%, fat mass fell 33.9%, and lean mass fell 10.9%. When you split the weight lost, roughly 75% was fat and 25% was lean mass, and that split held for the placebo group too. Single-agonist semaglutide sits in broadly the same range.

A 25% lean-mass share is a useful anchor, but it is not a fixed law. A 2024 review in the same journal looked across GLP-1-based therapies and found the lean-mass figure ranges widely between studies, from about 15% or less of total weight lost at one end to 40% or even 60% at the other^[3]. The authors argued that most of this muscle reduction looks adaptive, meaning it tracks the amount of weight lost and the person's age and health rather than signalling a drug-specific attack on muscle.

Why 'muscle loss' is a slippery term here

Two things get blurred in the question. First, lean mass and muscle are not the same thing. DXA measures fat-free mass, which includes water, organ tissue, and connective tissue, not just skeletal muscle, so a drop in lean mass on a scan overstates how much actual muscle is gone. Second, some fat-free mass loss accompanies almost any meaningful weight loss, including through diet and surgery. The retatrutide obesity trials that produced the headline weight numbers, such as the 24.2% mean loss at 48 weeks in the Phase 2 obesity study^[4], did not publish DXA body-composition data at all, so the muscle question there is genuinely unanswered.

What we do not yet know is substantial. There is no published body-composition readout from the large Phase 3 TRIUMPH obesity trials, and a 2025 systematic review of retatrutide covering three trials and 691 participants reported weight, BMI, and waist changes but no lean-mass detail^[5]. Whether the glucagon-receptor arm of retatrutide, which is what sets it apart from semaglutide and tirzepatide, changes the fat-to-lean ratio at scale is an open question.

One practical point the class literature does agree on: the muscle that comes off during weight loss responds to the usual levers. Resistance training and adequate protein intake are the standard tools for preserving lean mass while losing fat, and dedicated muscle-sparing drug combinations are in development. None of that is specific to retatrutide, and none of it is a reason to source an investigational compound outside a trial.

Where this lands

On the evidence available today, retatrutide does not appear to cause disproportionate muscle loss relative to the weight it removes, but the dataset is one small substudy in people with type-2 diabetes, not the general-obesity population most readers are asking about. If you are weighing this up, the regulatory reality matters as much as the body-composition one: see the retatrutide regulation status for where the compound stands, and talk to a clinician before making any decision about a drug that is not yet approved anywhere.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.